Other articles

Pliant Takes Late-Stage Route After Bexotegrast Issue And Slashes Workforce by 45%

Immunic Might Still Have Path Forward In PMS After Primary Endpoint Miss

Abeona Receives FDA Approval Of ZEVASKYN Marking A First

Positive Sasanlimab Data From Pfizer Could Bring New Medicine For High-Risk Bladder Cancer

Caribou Cuts Workforce And Puts Focus To lead Oncology Candidates

Genentech Aims For DECODE Platform From Repertoire In $765 Million Deal

Bristol-Myers Squibb Fails Phase 3 Study With Cobenfy

In Flight To Enact Strategic Alternatives, Tempest Cuts 80% of its Workforce

Eli Lilly’s Orforglipron Delivers Efficacy Similar To That Of Injectable GLP-1 Drugs

Despite Primary Endpoint Falling Short, Sanofi Moving Amlitelimb Forward

Mural Oncology Mulls Strategic Alternatives After Latest Failure With IL-2 Candidate

Pfizer Shelves GLP-1 Obesity Drug After Liver Injury In A Patient

Annexon’s C1q Targeting Of Complement System Could Bring About First Treatment For GBS

Bristol-Myers Squibb Puts Its Hat Into The Ring In Targeting 1st-Line Liver Cancer With OPDIVO-Based Regimen

Opthea Runs Out Of Options With Failed Wet-AMD Studies, Reduces Workforce By 65%

To Get Phase 3 Program Going Tempest Seeks Strategic Alternatives For Amezalpat For Liver Cancer

Bristol-Myers Squibb Nabs FDA Regulatory Wins With OPDIVO And Yervoy Combination For CRC

Photo by Tima Miroshnichenko from Pexels

Rallybio Scraps Maternal Disorder Candidate RLYB212 Shifting Focus To C5 Inhibitor

Photo by Ivan Samkov from Pexels

Rhythm Pharmaceuticals Scores A Win For Obesity Disorder Caused By Impairment Of The Brain

Photo by Polina Tankilevitch from Pexels

Beigene’s Anti-TIGIT Trial Closure Doesn’t Bode Well For This Drug Class Going Forward

Scroll to Top